CD274 and neoplasm: We demonstrate that effective antitumor response in the presence of high tumor burden requires concomitant treatment of GAd vaccine with immunomodulatory molecules able to counteract the immune-suppressive tumor microenvironment, such as anti-PD1 or anti-PDL1 antibodies.